Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 3 clients • 5 examiners • 3 art units • 0 of 5 (0%) have an AI response strategy ready
Kern Kendrick, LLC has managed 243 career applications, primarily in the Biotechnology & Pharmaceuticals technology area. The firm has a resolved allowance rate of 70.69 percent. This is achieved with an average of 2.56 office actions per allowance. Currently, the firm has 4 pending office actions.
The 70.69 percent allowance rate and the 2.56 office actions per allowance figure provide a clear picture of the firm's historical prosecution outcomes. These metrics are useful for understanding the typical effort and success rate for biotechnology applications managed by the firm. With 243 career applications, the firm has an established history in this technical field. The 4 pending office actions indicate that the firm is still actively pursuing grants. These data points offer a grounded perspective on the firm's performance and the expected prosecution path for its clients.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YUEN, JACKY | 1 | 34.8% | +51.4% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| WAN, DEMING | 1 | 76.4% | +42.4% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19043217 | PROCESS FOR EVAPORATIVE CASTING | YUEN, JACKY | 146d overdue |
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | ARNOLD, ERNST V | 2d overdue |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | KIM, DANIELLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19043217 | PROCESS FOR EVAPORATIVE CASTING | YUEN, JACKY | 146d overdue |
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | ARNOLD, ERNST V | 2d overdue |
| 18674044 | MICROSPHERE FORMULATIONS COMPRISING LURASIDONE AND METHODS FOR MAKING AND USING THE SAME | BASQUILL, SEAN M | — |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | KIM, DANIELLE A | — |
| 18671687 | SYSTEM AND METHOD FOR REDUCTION OF MOISTURE IN POROUS MATERIALS | WAN, DEMING | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Oakwood Laboratories, LLC | 3 |
| Skuld LLC | 1 |
| Eambient, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1735 | 1 |
| 1614 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19043217 | PROCESS FOR EVAPORATIVE CASTING | Skuld LLC | YUEN, JACKY | 1735 | §103§112 | Non-Final OA | 146d overdue | Pending | Jan 31, 2025 |
| 18674044 | MICROSPHERE FORMULATIONS COMPRISING LURASIDONE AND METHODS FOR MAKING AND USING THE SAME | Oakwood Laboratories, LLC | BASQUILL, SEAN M | 1614 | §103DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18713417 | MICROSPHERE FORMULATIONS COMPRISING ASENAPINE AND METHODS FOR MAKING AND USING THE SAME | Oakwood Laboratories, LLC | KIM, DANIELLE A | 1613 | §103§112 | Non-Final OA | — | Pending | May 24, 2024 |
| 18671687 | SYSTEM AND METHOD FOR REDUCTION OF MOISTURE IN POROUS MATERIALS | Eambient, Inc. | WAN, DEMING | §112 | Non-Final OA | — | Pending | May 22, 2024 | |
| 18467283 | MICROSPHERE FORMULATIONS COMPRISING NALTREXONE AND METHODS FOR MAKING AND USING THE SAME | Oakwood Laboratories, LLC | ARNOLD, ERNST V | 1613 | §102§103§112 | Final Rejection | 2d overdue | Pending | Sep 14, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial